



# MUTATION RESEARCH - GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS

A section of Mutation Research

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

ISSN: 1383-5718

•	<b>Description</b>	<b>p.1</b>
•	<b>Audience</b>	<b>p.1</b>
•	<b>Impact Factor</b>	<b>p.2</b>
•	<b>Abstracting and Indexing</b>	<b>p.2</b>
•	<b>Editorial Board</b>	<b>p.2</b>
•	<b>Guide for Authors</b>	<b>p.4</b>

### DESCRIPTION

*Mutation Research - Genetic Toxicology and Environmental Mutagenesis* publishes papers advancing knowledge in the field of genetic toxicology. Papers are welcomed in the following areas:

New developments in genotoxicity testing of chemical agents (e.g. improvements in methodology of assay systems and interpretation of results). Alternatives to and refinement of the use of animals in genotoxicity testing. Nano-genotoxicology, the study of genotoxicity hazards and risks related to novel man-made nanomaterials. Studies of epigenetic changes in relation to genotoxic effects. The use of structure-activity relationships in predicting genotoxic effects. The isolation and chemical characterization of novel environmental mutagens. The measurement of genotoxic effects in human populations, when accompanied by quantitative measurements of environmental or occupational exposures. The application of novel technologies for assessing the hazard and risks associated with genotoxic substances (e.g. OMICS or other high-throughput approaches to genotoxicity testing).

*Mutation Research - Genetic Toxicology and Environmental Mutagenesis* is now accepting submissions for a new section of the journal that will be dedicated to the discussion of current issues relating to design, interpretation and strategic use of genotoxicity tests (**Current Topics in Genotoxicity Testing**). This section is envisaged to include discussions relating to the development of new international testing guidelines, but also to wider topics in the field. The evaluation of contrasting or opposing viewpoints is welcomed as long as the presentation is in accordance with the journal's aims, scope, and policies.

#### Benefits to authors

We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our [author services](#).

Please see our [Guide for Authors](#) for information on article submission. If you require any further information or help, please visit our support pages: <http://support.elsevier.com>

### AUDIENCE

Environmental Scientists, Occupational Health Researchers, Mutageneticists, Toxicologists

## IMPACT FACTOR

---

2013: 2.481 © Thomson Reuters Journal Citation Reports 2014

## ABSTRACTING AND INDEXING

---

BIOSIS  
Chemical Abstracts  
Current Contents/Life Sciences  
MEDLINE®  
EMBASE  
PASCAL M  
Reference Update  
Scopus  
EMBiology

## EDITORIAL BOARD

---

### *Genetic Toxicology and Environmental Mutagenesis*

#### **EDITORS:**

**G. Jenkins**, Swansea University, Singleton Park, SA2 8PP, Swansea, Wales, UK

**P.D. Josephy**, Dept. of Molecular & Cellular Biology, College of Biological Science, University of Guelph, 50 Stone Road East, Guelph, ON N1G 2W1, Canada, Fax: +1 519 837 1802

#### **SPECIAL ISSUE EDITOR:**

**D.J. Kirkland**, Genetic Toxicology Consulting, Kirkland Consulting, P.O. Box 79, Tadcaster, North Yorkshire, LS24 0AS, England, UK

#### **FOUNDING EDITOR:**

**F.H. Sobels**

#### **EDITORIAL BOARD**

**D. Averbek**, Orsay Cedex, France

**A.B. Britt**, Davis, California, USA

**T.A. Cebula**, College Park, Maryland, USA

**W.N. Choy**, Lafayette, New Jersey, USA

**M.C. Cimino**, Washington, District of Columbia, USA

**A.R. Collins**, Oslo, Norway

**M.L. Cunningham**, Research Triangle Park, North Carolina, USA

**A.K. Dhawan**, Ahmedabad, Gujarat, India

**S.H. Doak**, Swansea, Wales, UK

**Y.E. Dubrova**, Leicester, UK

**D.A. Eastmond**, Riverside, California, USA

**G.L. Erexson**, North Chicago, Illinois, USA

**S. de Flora**, Genova, Italy

**K. Fujikawa**, Higashi-Osaka, Japan

**J. Gallagher**, Research Triangle Park, North Carolina, USA

**J.B. Guttenplan**, New York, New York, USA

**S. Hamada**, Kamisu-shi, Ibaraki-ken, Japan

**A. Hartmann**, Basel, Switzerland

**J. He**, Hangzhou, China

**Y. Ibuki**, Suruga-ku, Shizuoka-Shi, Japan

**A.N. Jha**, Plymouth, UK

**K. Kawai**, Kitakyushu-shi, Fukuoka, Japan

**A. Kligerman**, Research Triangle Park, North Carolina, USA

**S. Knasmüller**, Wien, Austria

**M.G. Manjanatha**, Jefferson, Arkansas, USA

**F. Marchetti**, Berkeley, California, USA

**H.J. Martus**

**K. Matsumoto**

**T. Morita**, Tokyo, Japan

**K. Mortelmans**, Menlo Park, California, USA

**L. Mueller**, Basel, Switzerland

**K. Nakachi**, Hiroshima City, Japan  
**T. Nohmi**, Minato-ku, Tokyo, Japan  
**S. Oikawa**  
**F. Palitti**, Viterbo, Italy  
**C. Pueyo de la Cuesta**, Córdoba, Spain  
**A.M. Richard**, Research Triangle Park, North Carolina, USA  
**E. Rojas del Castillo**, Mexico DF, Mexico  
**A. Rothfuss**, Berlin, Germany  
**D. Shaughnessy**, Raleigh, North Carolina, USA  
**L.M. Sierra Zapico**, Oviedo, Spain  
**N.P. Singh**, Seattle, Washington, USA  
**G. Speit**, Ulm, Germany  
**S. Sutou**, Okayama, Japan  
**T. Takamura-Enya**, Kanagawa, Japan  
**D. Tavares**, Franca, São Paulo, Brazil  
**V Thybaud**, Vitry sur Seine Cedex, France  
**J. Topinka**, Prague, Czech Republic  
**M.Z. Vasquez**, Morrisville, North Carolina, USA  
**L. Verschaeve**, Brussels, Belgium  
**K.K. Vijayalaxmi**, San Antonio, Texas, USA  
**K.L. Witt**, Research Triangle Park, North Carolina, USA  
**L.J. Wu**, Hefei, Anhui, China  
**M. Yamada**  
**E. Zeiger**, Chapel Hill, North Carolina, USA

## GUIDE FOR AUTHORS

---

### INTRODUCTION

*Mutation Research - Genetic Toxicology and Environmental Mutagenesis* publishes papers advancing knowledge in the field of genetic toxicology. Papers are welcomed in the following areas:

New developments in genotoxicity testing of chemical agents (e.g. improvements in methodology of assay systems and interpretation of results). Alternatives to and refinement of the use of animals in genotoxicity testing. Nano-genotoxicology, the study of genotoxicity hazards and risks related to novel man-made nanomaterials. Studies of epigenetic changes in relation to genotoxic effects. The use of structure-activity relationships in predicting genotoxic effects. The isolation and chemical characterization of novel environmental mutagens. The measurement of genotoxic effects in human populations, when accompanied by quantitative measurements of environmental or occupational exposures. The application of novel technologies for assessing the hazard and risks associated with genotoxic substances (e.g. OMICS or other high-throughput approaches to genotoxicity testing).

*Mutation Research - Genetic Toxicology and Environmental Mutagenesis* is now accepting submissions for a new section of the journal that will be dedicated to the discussion of current issues relating to design, interpretation and strategic use of genotoxicity tests (**Current Topics in Genotoxicity Testing**). This section is envisaged to include discussions relating to the development of new international testing guidelines, but also to wider topics in the field. The evaluation of contrasting or opposing viewpoints is welcomed as long as the presentation is in accordance with the journal's aims, scope, and policies.

### Types of Paper

*Mutation Research - Genetic Toxicology and Environmental Mutagenesis* publishes the following types of article: (I) Research papers- papers reporting results of original, fundamental research. (II) Short communications of up to 5 printed pages. (III) Rapids - are accelerated publications - research papers identified by the Editor as being of significant quality and thereby qualifying for rapid reviewing, and publication within 8-10 weeks of acceptance. (IV) Current issues are generally short, 1-2 page comments on a topical theme, and are published within 10 weeks of acceptance. (V) Volunteered and invited Mini-reviews of less than 10 printed pages, using references generally no later than 2 years old. The journal accepts Letters to the Editor.

Please note that Full-length reviews comprehensively covering and critically analysing a topic are published in *Mutation Research Reviews*. Also published in the Reviews section are invited papers in the series *Reflections in Mutation Research*, in which research and techniques that have played an important part in the development of the field of mutation research are revisited and their significance discussed. Special issues, comprising multiple original and/or review articles written from a particular viewpoint, on a central theme, are published on a regular basis in the appropriate section of *Mutation Research* by topic or article type.

Any submissions that report the results of studies on extracts or complex mixtures (e.g., solvent extracts of herbal preparations; soil, air, or water samples) will receive preliminary review by an Editor. Unless such manuscripts offer significant new insight, such as the chemical identification of previously unknown mutagens or anti-mutagens, they will be returned to the authors without being sent for further review. For further clarification of this journal policy please refer to the [Editorial](#) published in *Mutation Research* 391 (1997) 1.

It is the policy of the Editors to conduct a preliminary review of each submitted manuscript that reports the results of molecular epidemiology studies.

(i) As with any studies involving human subjects, approval by an appropriately constituted ethics review board and informed consent by participants are required.

(ii) Authors are advised to collaborate with qualified epidemiologists with respect to study design and interpretation.

(iii) In studies of the potential genotoxic effects of exposure to environmental agents, it is strongly recommended that quantitative evidence of exposure (such as analysis of personal monitoring devices or measurement of urinary biomarkers, for example) be obtained.

Manuscripts which do not conform to these requirements will be returned to the authors without being sent for further review.

## BEFORE YOU BEGIN

### **Ethics in publishing**

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

### **Conflict of interest**

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <http://www.elsevier.com/conflictsofinterest>.

The Journal requires full disclosure of all potential conflicts of interest. Please declare any financial or personal interests that might be viewed to inappropriately influence the work presented. Interests could include employment, consultancies, stock ownership and honoraria. If there are no conflicts of interest, the authors should state, "The authors declare that there are no conflicts of interest". If there are any financial or personal interests please state so here and include this statement as an Acknowledgement in your submitting manuscript. Signed copies of the *Mutation Research-Genetic Toxicology and Environmental Mutagenesis* Conflict of Interest policy form are required upon submission. The Conflict of Interest policy form can be downloaded [here](#). In order to minimize delays, we strongly advise that the signed copies of these statements are prepared before you submit your manuscript.

### **Submission declaration**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

A Chinese version of the submission instructions for MUTGEN can be found [here](#).

### **Changes to authorship**

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

### **Copyright**

This journal offers authors a choice in publishing their research: Open access and Subscription.

#### *For subscription articles*

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <http://www.elsevier.com/copyright>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations

(please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

#### *For open access articles*

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <http://www.elsevier.com/OAauthoragreement>). Permitted reuse of open access articles is determined by the author's choice of user license (see <http://www.elsevier.com/openaccesslicenses>).

#### **Retained author rights**

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articles please see <http://www.elsevier.com/journal-authors/author-rights-and-responsibilities>.  
Open access articles please see <http://www.elsevier.com/OAauthoragreement>.

#### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

#### **Funding body agreements and policies**

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

#### **Open access**

This journal offers authors a choice in publishing their research:

##### **Open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or their research funder

##### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (<http://www.elsevier.com/access>)
- No open access publication fee

All articles published open access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

**Creative Commons Attribution (CC BY):** lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

**Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA):** for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND):** for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access.

Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The publication fee for this journal is **\$3000**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

### **Submission**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.

### **Referees**

The Editors welcome submissions by the authors of the names and addresses of up to four individuals who could expertly review the paper, and who are not from the same institutions as the authors. The Editors reserve the right to use these or other reviewers.

### **Free access to scientific publications for public institutions in developing countries:**

The Health InterNetwork Access to Research Initiative (HINARI) is an initiative to provide free or nearly free access to the major journals in biomedical and related social sciences, to public institutions in developing countries. Starting in January 2002 with over 2000 journals from Elsevier and other leading biomedical publishers, HINARI is part of the Health InterNetwork, which was introduced by the United Nations' Secretary General Kofi Annan at the UN Millennium Summit in the year 2000.

For further information and registration, please check the HINARI site: <http://www.who.int/hinari/en/>

## **PREPARATION**

### **Use of word processing software**

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

### **Article structure**



### *Subdivision - numbered sections*

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

### *Results*

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

### *Appendices*

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

### **Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### **Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself. **The abstract should be up to 300 words of size.**

### **Graphical abstract**

A Graphical abstract is optional and should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See <http://www.elsevier.com/graphicalabstracts> for examples.



Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images also in accordance with all technical requirements: [Illustration Service](#).

### **Highlights**

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See <http://www.elsevier.com/highlights> for examples.

### **Keywords**

Immediately after the abstract, provide between 3 to 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

### **Abbreviations**

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

### **Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

### **Database linking**

Elsevier encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See <http://www.elsevier.com/databaselinking> for more information and a full list of supported databases.

### **Math formulae**

Present simple formulae in the line of normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

### **Footnotes**

Footnotes should be used sparingly. Number them consecutively throughout the article, using superscript Arabic numbers. Many wordprocessors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

#### **Table footnotes**

Indicate each footnote in a table with a superscript lowercase letter.

### **e-CRC**

*General points:* Elsevier can only accept MS Word, LaTeX, or postscript/PDF documents as electronic camera-ready copy (e-CRC). Electronic files can be stored on CD or may be transferred to Elsevier via FTP (details available from Customer support: <http://support.elsevier.com>). Please note: always send the source file (Word or LaTeX) together with any PDF files as this can contribute to better quality final PDF files and help in the conversion to XML.

*MS Word file:* Please ensure that you use normal fonts as much as possible in your documents, such as Times New Roman, Arial, Symbol, Helvetica, or Times (TrueType or Type 1 fonts). Special fonts, such as those used in the Far East (Japanese, Chinese, Korean, etc.) may cause problems during processing. If you use a lot of special fonts, please convert the document to PDF with Adobe Acrobat (see below, and also Elsevier's Quickguide: <http://www.elsevier.com/guidepublication>). Please place figures in a logical place within the document (see also the section on *Preparation of electronic illustrations* at <http://www.elsevier.com/artworkinstructions>). To avoid unnecessary errors you are strongly advised to use the 'spell-checker' function of your wordprocessor.

**LaTeX documents:** Please use a LaTeX setup that uses Type 1 fonts instead of the sometimes default bitmap fonts (Type 3, or pk fonts). For instance, using the LaTeX Times package may be enough to enable this adjustment. For information on LaTeX see <http://www.elsevier.com/latex>. Please provide all document-related and temporary files on submission, as well as the resulting postscript or PDF file.

**Postscript/PDF files:** Please create postscript files, making sure all fonts are embedded. When creating PDF files with Adobe Acrobat, please use version 4.05 or higher, and use the standard "Press Optimized" settings, as provided by Adobe.

## Artwork

### Electronic artwork

#### General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the printed version.
- Submit each illustration as a separate file.

A detailed guide on electronic artwork is available on our website:

<http://www.elsevier.com/artworkinstructions>

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

#### Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

#### Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) and in the printed version (unless you specify otherwise). Please indicate your preference for color: in print and on the Web, or on the Web only. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

Please note: Because of technical complications which can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

#### Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

## Tables

Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

## References

### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

### *Reference links*

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

### *Reference management software*

This journal has standard templates available in key reference management packages EndNote (<http://www.endnote.com/support/enstyles.asp>) and Reference Manager (<http://refman.com/support/rmstyles.asp>). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

### *Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume and issue/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

### *Reference style*

**Text:** Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'

**List:** Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

### *Examples:*

Reference to a journal publication:

[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun. 163 (2010) 51–59.

Reference to a book:

[2] W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 2000.

Reference to a chapter in an edited book:

[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 2009, pp. 281–304.

### *Journal abbreviations source*

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>.

### Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### AudioSlides

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <http://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

### Supplementary data

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

### Submission Checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Phone numbers

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)
- Color figures are clearly marked as being intended for color reproduction on the Web and in print, or to be reproduced in color on the Web and in black-and-white in print. There are no color charges for Web and/or print reproduction
- If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at <http://support.elsevier.com>.

### AFTER ACCEPTANCE

### **Use of the Digital Object Identifier**

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately - please upload all of your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

### **Offprints**

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on [ScienceDirect](#). This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (<http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (<http://webshop.elsevier.com/myarticleservices/booklets>).

### **AUTHOR INQUIRIES**

You can track your submitted article at [http://help.elsevier.com/app/answers/detail/a\\_id/89/p/8045/](http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/). You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

© Copyright 2014 Elsevier | <http://www.elsevier.com>